Effects of doxercalciferol: A Synthesis of Findings from 29 Studies

  1. Home
  2. Effects of doxercalciferol
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of doxercalciferol: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of doxercalciferol: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Key research findings

Doxercalciferol is a vitamin D2 analog that has been shown to be effective in treating secondary hyperparathyroidism in patients with kidney disease. , 22 , 13 Compared to calcitriol, doxercalciferol has been reported to have fewer effects on blood calcium levels and a higher ability to suppress parathyroid hormone. 17 Doxercalciferol may also be beneficial for improving bone metabolism, increasing fibroblast growth factor 23 (FGF-23), and reducing vascular calcification. 1 , 3 Doxercalciferol has also shown potential for the treatment of acute myeloid leukemia (AML). 16 , 24 , 21 When combined with cytarabine, doxercalciferol has been shown to enhance the suppression of AML cell growth and induce apoptosis. 24 , 21 Doxercalciferol has shown potential for the treatment of hepatocellular carcinoma. 9 When combined with sorafenib, doxercalciferol has been shown to enhance the suppression of hepatocellular carcinoma cell growth and induce apoptosis. 9 Doxercalciferol has also been shown to have antibacterial effects. 19 When combined with bacitracin, doxercalciferol has been shown to enhance the suppression of mutans streptococci growth. 19

Benefits and Risks

Benefit Summary

Doxercalciferol has been shown to be effective in treating secondary hyperparathyroidism in patients with kidney disease. , 22 , 13 Compared to calcitriol, doxercalciferol has been reported to have fewer effects on blood calcium levels and a higher ability to suppress parathyroid hormone. 17 Doxercalciferol may also be beneficial for improving bone metabolism, increasing fibroblast growth factor 23 (FGF-23), and reducing vascular calcification. 1 , 3 Doxercalciferol has also shown potential for the treatment of acute myeloid leukemia (AML). 16 , 24 , 21 When combined with cytarabine, doxercalciferol has been shown to enhance the suppression of AML cell growth and induce apoptosis. 24 , 21 Doxercalciferol has shown potential for the treatment of hepatocellular carcinoma. 9 When combined with sorafenib, doxercalciferol has been shown to enhance the suppression of hepatocellular carcinoma cell growth and induce apoptosis. 9 Doxercalciferol has also been shown to have antibacterial effects. 19 When combined with bacitracin, doxercalciferol has been shown to enhance the suppression of mutans streptococci growth. 19

Risk Summary

Compared to calcitriol, doxercalciferol has been reported to have fewer effects on blood calcium levels and a higher ability to suppress parathyroid hormone. 17 However, doxercalciferol has been shown to be less effective than calcitriol in controlling blood phosphate levels. 17 High doses of doxercalciferol can increase the risk of hypercalcemia and hyperphosphatemia. 26 , 22 Doxercalciferol is not recommended for use in pregnant or breastfeeding women. 22

Comparison of Studies

Similarities of Studies

Many studies have shown that doxercalciferol is effective in treating secondary hyperparathyroidism in patients with kidney disease. , 22 , 13 Compared to calcitriol, doxercalciferol has been reported to have fewer effects on blood calcium levels and a higher ability to suppress parathyroid hormone. 17 Doxercalciferol may also be beneficial for improving bone metabolism, increasing fibroblast growth factor 23 (FGF-23), and reducing vascular calcification. 1 , 3

Differences in Studies

Doxercalciferol has been shown to be less effective than calcitriol in controlling blood phosphate levels. 17 High doses of doxercalciferol can increase the risk of hypercalcemia and hyperphosphatemia. 26 , 22 Doxercalciferol is not recommended for use in pregnant or breastfeeding women. 22

Consistency and Contradictions of Results

Many studies have shown that doxercalciferol is effective in treating secondary hyperparathyroidism in patients with kidney disease and has a better safety profile compared to calcitriol. , 22 , 13 , 17 However, there are also some inconsistencies. Some studies have shown that doxercalciferol is less effective than calcitriol in controlling blood phosphate levels. 17 Further research is needed to better understand the effects of doxercalciferol.

Notes on Application to Real Life

Doxercalciferol is a promising treatment option for secondary hyperparathyroidism in patients with kidney disease, but its use should be carefully monitored. , 22 , 13 It is important to note that doxercalciferol may not be as effective as calcitriol in controlling blood phosphate levels. 17 It is also important to be aware of the potential risks of hypercalcemia and hyperphosphatemia, especially when using high doses. 26 , 22 If you are considering using doxercalciferol, it is important to talk to your doctor about the potential benefits and risks.

Limitations of Current Research

More research is needed to better understand the long-term effects and safety of doxercalciferol. Further studies are also needed to evaluate the effectiveness and side effects of doxercalciferol in treating other diseases.

Future Research Directions

Future research should focus on the long-term effects and safety of doxercalciferol, the effectiveness and side effects of doxercalciferol in treating other diseases, and the optimal dose and route of administration. Research should also explore individual differences in response to doxercalciferol treatment.

Conclusion

Doxercalciferol is a promising treatment option for secondary hyperparathyroidism in patients with kidney disease. , 22 , 13 It is important to be aware of the potential risks of hypercalcemia and hyperphosphatemia, especially when using high doses. 26 , 22 Doxercalciferol may not be as effective as calcitriol in controlling blood phosphate levels. 17 If you are considering using doxercalciferol, it is important to talk to your doctor about the potential benefits and risks.

Keywords
Benefit Keywords
Secondary hyperparathyroidism treatment
2
Controlled serum PTH
Suppressed bone formation rate
3
Improved renal osteodystrophy
4
Reduced Parathyroid Hormone Levels
5
Improved bone lesions
Reduced PTH levels
6
Corrected vitamin D deficiency
Improved bone disease
Suppressed parathyroid activity
7
Reduced mortality
8
HCC treatment
9
Pleiotropic effects
SHPT prevention
10
Bone disease prevention
12
Cardiovascular benefits
Vitamin D treatment
13
CKD treatment
14
Reduced missed doses
SHPT management
15
AML treatment
16
Calcium regulation
PTH suppression
17
Hyperparathyroidism treatment
18
Streptococcus mutans lysis
19
SHPT treatment
20
AML treatment
21
Secondary hyperparathyroidism management
22
Vitamin D metabolism
23
Increased differentiation potency
No increased hypercalcemic properties
24
Cardio-renal protection
25
Reduced hypercalcemia
iPTH suppression
26
Kidney disease treatment
27
Improved bone health
28
AD prevention
29
Risk Keywords
Vascular calcification
1
Geographic variation
2
Increased FGF-23
3
Hypercalcemia
Hyperphosphatemia
Parathyroid hyperplasia
4
Increased Calcium Levels
Increased Phosphorus Levels
5
Hypercalcemia
Increased Ca x P
6
Hypercalcemia
7
Calcium and phosphorus balance
Toxicity
8
Mortality
Skeletal fractures
Unsatisfactory results
10
Toxicity
11
Hypercalcemia
Kidney function
12
Calcium and phosphate increase
13
Increased calcium
Increased phosphorus
14
Hyperphosphatemia
17
Side effects
20
Adynamic bone disease
Hypercalcemia
Renal insufficiency progression
Soft tissue calcification
Vascular calcification
22
Hypercalcaemia
25
Hyperphosphatemia
26
Calcium overload
28
Literature analysis of 29 papers
Positive Content
23
Neutral Content
4
Negative Content
2
Article Type
3
3
3
10
29
1.

Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.

Author: NoonanWilliam, KochKristin, NakaneMasaki, MaJunli, DixonDoug, BolinAntoinette, ReinhartGlenn

Vascular calcification

Paricalcitol and doxercalciferol, vitamin D receptor activators, had different effects on aortic calcification in a rat model of chronic kidney disease. Paricalcitol reduced aortic calcification and improved aortic compliance, while doxercalciferol had no significant effect.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Trends and variations in intravenous vitamin D use among hemodialysis patients in the United States.

Author: BeaubrunAnne C, BrookhartM Alan, SleathBetsy, WangLily, KshirsagarAbhijit V

Secondary hyperparathyroidism treatment
Geographic variation

This study describes patterns and variations in the use of vitamin D formulations (calcitriol, paricalcitol, and doxercalciferol) in hemodialysis patients in the United States. Paricalcitol was the most frequently used formulation, and significant variations were observed in the geographic distribution of vitamin D doses.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

3.

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.

Author: Wesseling-PerryKatherine, PereiraRenata C, SahneyShobha, GalesBarbara, WangHe-Jing, ElashoffRobert, JüppnerHarald, SaluskyIsidro B

Controlled serum PTH
Suppressed bone formation rate
Increased FGF-23

This study compared the effects of calcitriol and doxercalciferol, in combination with either calcium carbonate or sevelamer, on bone, mineral, and fibroblast growth factor-23 (FGF-23) metabolism in patients with secondary hyperparathyroidism. Doxercalciferol was as effective as calcitriol in controlling serum parathyroid hormone levels and suppressing the bone formation rate. Sevelamer allowed the use of higher doses of vitamin D.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

What is the optimal regimen for vitamin D?

Author: CunninghamJ

Improved renal osteodystrophy
Hypercalcemia
Hyperphosphatemia
Parathyroid hyperplasia

New vitamin D metabolites, such as 22-oxacalcitriol, paricalcitol, and doxercalciferol, have shown high efficacy when compared with placebo, but further research is needed to determine their superiority over current standard therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Vitamin D compounds for people with chronic kidney disease not requiring dialysis.

Author: PalmerSuetonia C, McGregorDavid O, CraigJonathan C, ElderGrahame, MacaskillPetra, StrippoliGiovanni Fm

Reduced Parathyroid Hormone Levels
Increased Calcium Levels
Increased Phosphorus Levels

Vitamin D compounds reduced serum parathyroid hormone (PTH) in people with chronic kidney disease (CKD) not requiring dialysis. However, the effect on mortality, cardiovascular outcomes, and the balance between PTH reduction and increased serum phosphorus and calcium remain unclear.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

6.

Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.

Author: SaluskyIsidro B, GoodmanWilliam G, SahneyShobha, GalesBarbara, PerillouxAshley, WangHe-Jing, ElashoffRobert M, JüppnerHarald

Improved bone lesions
Reduced PTH levels
Hypercalcemia
Increased Ca x P

This study compared the effects of calcium carbonate and sevelamer on skeletal lesions in pediatric peritoneal dialysis patients with secondary hyperparathyroidism. Both binders improved skeletal lesions, but sevelamer maintained serum calcium levels within a safer range.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

7.

Vitamin D metabolites and/or analogs: which D for which patient?

Author: MazzaferroS, GoldsmithD, LarssonT E, MassyZ A, CozzolinoM

Corrected vitamin D deficiency
Improved bone disease
Suppressed parathyroid activity
Hypercalcemia

This paper reviews the characteristics and potential clinical indications of various vitamin D drugs, focusing on renal patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Vitamin d receptor activators and clinical outcomes in chronic kidney disease.

Author: GravelloneLuciana, RizzoMaria Antonietta, MartinaValentina, MezzinaNicoletta, RegaliaAnna, GallieniMaurizio

Reduced mortality
Calcium and phosphorus balance
Toxicity

Vitamin D analogs may have beneficial effects in hemodialysis patients, but further research is needed to confirm their effectiveness.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

9.

Enhancement of sorafenib-mediated death of Hepatocellular carcinoma cells by Carnosic acid and Vitamin D2 analog combination.

Author: WuQunfeng, WangXuening, PhamKien, LunaAesis, StudzinskiGeorge P, LiuChen

HCC treatment

This study investigated the combination of Doxercalciferol (D2), a vitamin D2 analog, with carnosic acid (CA) and sorafenib (Sf) for treating hepatocellular carcinoma (HCC). The combination increased HCC cell death, enhancing autophagy and apoptosis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

10.

[Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease].

Author: Ureña-TorresPablo Antonio, CozzolinoMario, BoverJordi

Pleiotropic effects
SHPT prevention
Mortality
Skeletal fractures
Unsatisfactory results

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD). While vitamin D derivatives are often used to prevent and treat SHPT, their effectiveness is debated. This review highlights the need for further research on the effects of nutritional vitamin D and vitamin D receptor activators (VDRA) on hard endpoints in CKD patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : French

11.

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.

Author: AttiaSteven, EickhoffJens, WildingGeorge, McNeelDouglas, BlankJules, AhujaHarish, JumonvilleAlcee, EastmanMichael, ShevrinDaniel, GlodeMichael, AlbertiDona, StaabMary Jane, HorvathDottie, StrausJane, MarnochaRebecca, LiuGlenn

Toxicity

Doxercalciferol did not improve PSA response rate or survival when combined with docetaxel in men with androgen-independent prostate cancer. Toxicity was similar in both groups.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Effect of Vitamin D Receptor Activators on Glomerular Filtration Rate: A Meta-Analysis and Systematic Review.

Author: ZhangQian, LiMing, ZhangTiansong, ChenJing

Bone disease prevention
Hypercalcemia
Kidney function

Administration of VDRAs increased serum creatinine levels. Subgroup analysis of studies that did not use SCr-based measures did not indicate a lower GFR in the VDRA group. Patients receiving VDRAs had lower eGFR (weighted mean difference WMD -1.29 mL/min /1.73 m2, 95% CI -2.42 to -0.17) and elevated serum creatinine (WMD 7.03 μmol/L, 95% CI 0.61 to 13.46).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

13.

New vitamin D analogs and changing therapeutic paradigms.

Author: CunninghamJohn, ZehnderDaniel

Cardiovascular benefits
Vitamin D treatment
Calcium and phosphate increase

The study found that selective vitamin D compounds with minimal effects on mineral metabolism and with maximal cardiovascular and renal benefits are needed. Current clinical use of vitamin D compounds is limited to paricalcitol, 22-oxacalcitriol, and doxercalciferol.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

Vitamin D compounds for people with chronic kidney disease requiring dialysis.

Author: PalmerSuetonia C, McGregorDavid O, CraigJonathan C, ElderGrahame, MacaskillPetra, StrippoliGiovanni Fm

CKD treatment
Increased calcium
Increased phosphorus

Guidelines recommend vitamin D for managing chronic kidney disease (CKD) by lowering parathyroid hormone levels, but this treatment may increase phosphorus and calcium levels, which have been linked to higher death rates in observational studies. However, these studies also suggest that vitamin D treatment may be linked to lower death rates in CKD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

15.

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.

Author: MittmanNeal, DesirajuBrinda, MeyerKevin B, ChattopadhyayJyoti, AvramMorrell M

Reduced missed doses
SHPT management

This study compares the long-term use of calcitriol and paricalcitol in hemodialysis patients with secondary hyperparathyroidism (SHPT). Switching from calcitriol to paricalcitol resulted in lower serum calcium, phosphorus, and parathyroid hormone levels, along with a significant reduction in missed doses.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Involvement of microRNA181a in differentiation and cell cycle arrest induced by a plant-derived antioxidant carnosic acid and vitamin D analog doxercalciferol in human leukemia cells.

Author: DuggalJyoti, HarrisonJonathan S, StudzinskiGeorge P, WangXuening

AML treatment

Doxercalciferol (1-D2) is a drug that is being investigated as a treatment for acute myeloid leukemia (AML). This study found that 1-D2 could induce differentiation of AML cells, which means that the cells become more like normal blood cells. The study also found that carnosic acid, a plant-derived antioxidant, could enhance the effects of 1-D2. This study suggests that 1-D2, with or without carnosic acid, could be a promising new treatment for AML.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Mortality risk among hemodialysis patients receiving different vitamin D analogs.

Author: TentoriF, HuntW C, StidleyC A, RohrscheibM R, BedrickE J, MeyerK B, JohnsonH K, ZagerP G,

Hyperparathyroidism treatment

Doxercalciferol and paricalcitol were found to be equally effective in reducing mortality in hemodialysis patients with secondary hyperparathyroidism compared to calcitriol. Mortality was higher in patients who did not receive vitamin D therapy.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Vitamin D Compounds Are Bactericidal against Streptococcus mutans and Target the Bacitracin-Associated Efflux System.

Author: SaputoS, FaustoferriR C, QuiveyR G

Streptococcus mutans lysis

Vitamin D analogs have lytic activity against Streptococcus mutans, a bacterium that contributes to dental caries. This study shows that doxercalciferol, a vitamin D derivative, acts synergistically with bacitracin to induce lysis of S. mutans.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Comparative review of the pharmacokinetics of vitamin D analogues.

Author: BailieGeorge R, JohnsonCurtis A

Vitamin D metabolism

This article reviews the pharmacokinetic characteristics of calcitriol, paricalcitol, and doxercalciferol, vitamin D analogs used in treating chronic kidney disease. Calcitriol and paricalcitol have similar pharmacokinetic profiles, with short half-lives. Doxercalciferol requires hepatic metabolism to its active metabolite, with a longer half-life. More research is needed to understand the disposition of these vitamin D analogs in specific populations, such as pediatric and geriatric dialysis patients.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

24.

BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents.

Author: WangXuening, HarrisonJonathan S, StudzinskiGeorge P

Increased differentiation potency
No increased hypercalcemic properties

Vitamin D or its derivatives (VDDs) are being investigated for their antineoplastic properties. This study found that BRAF is required for the optimally increased cell death in AML cells treated with Doxercalciferol and Carnosic Acid. This therapeutic regimen should be tested in a clinical trial.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Language : English

26.

Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.

Author: MaungH M, ElangovanL, FrazãoJ M, BowerJ D, KelleyB J, AcchiardoS R, RodriguezH J, NorrisK C, SigalaJ F, RutkowskiM, RobertsonJ A, GoodmanW G, LevineB S, ChesneyR W, MazessR B, KylloD M, DouglassL L, BishopC W, CoburnJ W

Reduced hypercalcemia
iPTH suppression
Hyperphosphatemia

Intravenous doxercalciferol (1alphaD(2)) effectively reduced parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. Compared to oral doxercalciferol, intravenous administration resulted in less frequent hypercalcemia and less increase in serum phosphorus levels.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Language : English

27.

Differential effects of oral doxercalciferol (Hectorol) or paricalcitol (Zemplar) in the Cyp27b1-null mouse model of uremia.

Author: St-ArnaudRené, ArabianAlice, AkhouayriOmar, KnutsonJoyce C, StrugnellStephen A

Kidney disease treatment

This study developed an animal model with complete calcitriol deficiency to evaluate vitamin D analogs in uremia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

28.

Pharmacotherapy of chronic kidney disease and mineral bone disorder.

Author: BarretoFellype Carvalho, de OliveiraRodrigo Azevedo, OliveiraRodrigo Bueno, JorgettiVanda

Improved bone health
Calcium overload

The treatment paradigm for CKD-mineral bone disorder has shifted with the introduction of noncalcium-containing phosphate binders, vitamin D receptor activators, and calcimimetics.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

29.

Vitamin D and Its Analogues Decrease Amyloid-β (Aβ) Formation and Increase Aβ-Degradation.

Author: GrimmMarcus O W, ThielAndrea, LauerAnna A, WinklerJakob, LehmannJohannes, RegnerLiesa, NelkeChristopher, JanitschkeDaniel, BenoistCéline, StreidenbergerOlga, StötzelHannah, EndresKristina, HerrChristian, BeisswengerChristoph, GrimmHeike S, BalsRobert, LammertFrank, HartmannTobias

AD prevention

This study investigated the effect of vitamin D and its analogues on amyloid-β (Aβ) production and degradation, relevant to Alzheimer's disease (AD). Both vitamin D and its analogues decreased Aβ production and increased its degradation in neuroblastoma cells and vitamin D-deficient mouse brains. The effects were mediated by reducing the activity of BACE1 and γ-secretase, enzymes involved in Aβ production. This suggests that vitamin D supplementation or its analogues may have beneficial effects in AD prevention.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.